Midodrine During Recovery From Septic Shock
- Registration Number
- NCT02771158
- Lead Sponsor
- Northwell Health
- Brief Summary
The purpose of this study is to determine whether midodrine administration decreases duration of intravenous vasopressors and intensive care unit length of stay for patients in septic shock.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- admitted to intensive care unit
- diagnosis of septic shock on intravenous vasopressors
- stable/decreasing doses of intravenous vasopressors
- stable/improving organ function
Exclusion Criteria
- allergy to midodrine
- multiple intravenous vasopressors
- increasing intravenous vasopressor requirements
- worsening organ dysfunction
- severe bradycardia
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description placebo placebo randomization to placebo control midodrine Midodrine randomization to midodrine 20 mg every 8 hours to be increased to a maximum of 40 mg every 8 hours until intravenous vasopressor discontinuation
- Primary Outcome Measures
Name Time Method duration of intravenous vasopressors from enrollment until discontinuation of intravenous vasopressors, expected to be 3-5 days
- Secondary Outcome Measures
Name Time Method intensive care unit length of stay from enrollment until eligible for discharge from intensive care unit, expected to be 4-7 days hospital length of stay from enrollment until hospital discharge, expected to be up to 30 days re-institution of intravenous vasopressor from enrollment until hospital discharge, expected to be up to 30 days midodrine side effects requiring discontinuation from enrollment until hospital discharge, expected to be up to 30 days including supine hypertension and bradycardia
mortality from enrollment until hospital discharge, expected to be up to 30 days